-
AC Immune SA NASDAQ:ACIU AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen.
Location: EPFL Innovation Park, Building B, Vaud, 1015, Switzerland | Website: www.acimmune.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
143.7M
Cash
157.9M
Avg Qtr Burn
N/A
Short % of Float
2.51%
Insider Ownership
21.84%
Institutional Own.
28.82%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PI-2620 Details Alzheimer's disease, Neurological disorder | Phase 3 Data readout | |
JNJ-2056 (prev. ACI-35.030 or JACI-35.054) (anti-pTau vaccine) Details Neurological disorder, Alzheimer's disease | Phase 2b Data readout | |
ACI-7104.056 Details Parkinson's disease | Phase 2 Data readout | |
Crenezumab Details Alzheimer's disease, Neurological disorder | Phase 2 Update | |
Semorinemab Details Neurological disorder, Alzheimer's disease | Phase 2 Update | |
ACI-24.060 (anti-Abeta vaccine) Details Neurological disorder, Alzheimer's disease, Down Syndrome | Phase 1/2 Update | |
AC1-3024 Details Neurological disorder | Failed Discontinued |